Literature DB >> 10556222

Incremental prognostic value of rest-redistribution (201)Tl single-photon emission computed tomography.

T Sharir1, D S Berman, H C Lewin, J D Friedman, I Cohen, R Miranda, R D Agafitei, G Germano.   

Abstract

BACKGROUND: The incremental prognostic value of rest-redistribution (201)Tl compared with stress and rest perfusion abnormalities has not been defined. METHODS AND
RESULTS: We identified 458 patients who underwent rest (201)Tl /stress (exercise or adenosine) (99m)Tc sestamibi single-photon emission computed tomography (SPECT) and had late (18 to 24 hours) (201)Tl imaging, were not revascularized within 60 days of SPECT, and were followed up at >1 year. SPECT images were visually analyzed with the use of a 20-segment model on a scale of 0 to 4. Thirty-seven cardiac deaths (CDs) and 17 nonfatal myocardial infarctions occurred. Univariate Cox proportional hazards analysis showed that the presence of a large amount of rest (201)Tl reversibility (rest-late summed difference score [SDS] of >8) was a significant predictor of CD (chi(2) = 5.77, P = 0.02) and CD or myocardial infarction (chi(2) = 5.3, P = 0.02). The CD rate was 9.3% y(-1) in patients with rest-late SDS of >8 compared with 3.6% y(-1) in patients with a mild/moderate amount of rest reversibility (rest-late SDS 3 to 8) and 3.4% y(-1) in patients with no rest reversibility (rest-late SDS <3) (P = 0.029). Kaplan-Meier survival analysis demonstrated significantly lower cumulative survival rates in patients with rest-late SDS of >8 (P = 0.01). Multivariate Cox proportional hazards analysis demonstrated that the presence of a large amount of resting reversibility was an independent and incremental predictor of CD after adjustment for stress and rest perfusion information. Multivariate logistic regression analysis demonstrated that resting reversibility was not an independent predictor of referral to coronary angiography and revascularization.
CONCLUSIONS: The identification of a large amount of resting (201)Tl reversibility is an independent predictor of CD over stress and rest perfusion abnormalities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556222     DOI: 10.1161/01.cir.100.19.1964

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  11 in total

1.  Risk stratification of the normal perfusion scan: does normal stress perfusion always mean very low risk?

Authors:  Seth Dahlberg; Jeffrey Leppo
Journal:  J Nucl Cardiol       Date:  2003 Jan-Feb       Impact factor: 5.952

2.  Quantitation of infarct size in patients with chronic coronary artery disease using rest-redistribution Tl-201 myocardial perfusion SPECT: correlation with contrast-enhanced cardiac magnetic resonance.

Authors:  David S Fieno; Louise E J Thomson; Piotr Slomka; Aiden Abidov; John D Friedman; Guido Germano; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2007-01       Impact factor: 5.952

3.  Consideration of perfusion reserve in viability assessment by myocardial Tl-201 rest-redistribution SPECT: a quantitative study with dual-isotope SPECT.

Authors:  Jin Chul Paeng; Dong Soo Lee; Gi Jeong Cheon; Ki Bong Kim; Jeong Seok Yeo; June-Key Chung; Myung Chul Lee
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

4.  Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial.

Authors:  Allen E Atchley; Ami E Iskandrian; Dan Bensimhon; Stephen J Ellis; Dalane W Kitzman; Linda K Shaw; Robert A Pagnanelli; David J Whellan; Julius M Gardin; Andrew Kao; Khaled Abdul-Nour; Greg Ewald; Mary Norine Walsh; William E Kraus; Christopher M O'Connor; Salvador Borges-Neto
Journal:  Am Heart J       Date:  2011-04-06       Impact factor: 4.749

5.  Serial changes on quantitative myocardial perfusion SPECT in patients undergoing revascularization or conservative therapy.

Authors:  D S Berman; X Kang; E F Schisterman; J Gerlach; P B Kavanagh; J S Areeda; T Sharir; S W Hayes; L J Shaw; H C Lewin; J D Friedman; R Miranda; G Germano
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

6.  Transient ischemic dilatation of the left ventricle with severe post stress left ventricular dysfunction in the setting of severe aortic stenosis and normal coronary arteries.

Authors:  Marcin Kowalski; Beth A Harkness; Karthik Ananthasubramaniam
Journal:  Int J Cardiovasc Imaging       Date:  2006-08-22       Impact factor: 2.357

7.  Rest perfusion defects in patients with no history of myocardial infarction predict the presence of a critical coronary artery stenosis.

Authors:  Fatma A Aboul-Enein; Sean W Hayes; Naoya Matsumoto; John D Friedman; Guido Germano; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2003 Nov-Dec       Impact factor: 5.952

8.  Resting perfusion MPI-SPECT combined with cardiac 123I-mIBG sympathetic innervation imaging improves prediction of arrhythmic events in non-ischemic cardiomyopathy patients: sub-study from the ADMIRE-HF trial.

Authors:  Nitesh Sood; Firas Al Badarin; Matthew Parker; Raja Pullatt; Arnold F Jacobson; Timothy M Bateman; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2013-07-18       Impact factor: 5.952

9.  Gated SPECT myocardial perfusion imaging with cadmium-zinc-telluride detectors allows real-time assessment of dobutamine-stress-induced wall motion abnormalities.

Authors:  Rene Nkoulou; Mathias Wolfrum; Aju P Pazhenkottil; Michael Fiechter; Ronny R Buechel; Oliver Gaemperli; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2018-01-16       Impact factor: 5.952

10.  Prognostic value of myocardial perfusion scintigraphy in type 2 diabetic patients with mild, stable angina pectoris.

Authors:  Jacobijne J Wiersma; Hein J Verberne; Wik L ten Holt; Ineke M Radder; Lea M Dijksman; Berthe L F van Eck-Smit; Mieke D Trip; Jan G P Tijssen; Jan J Piek
Journal:  J Nucl Cardiol       Date:  2009-06-18       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.